search
Back to results

The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

Primary Purpose

Gastroesophageal Reflux Disease

Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
Lansoprazole/Domperidone
Sponsored by
Neutec Ar-Ge San ve Tic A.Ş
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux Disease

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) during last one year with at least 1 or more episodes a week
  • Age ≥ 18 years and <65 years
  • Helicobacter pylori (an infection) negative
  • Have a body mass index (BMI) between 18 and 33 kg/m²
  • pH>4 gastric exposure <25% on a 24-hour dual pH channel monitoring study performed prior to screening (normal intragastric pH +2SD)
  • Pathologic intraesophageal acidity exposure (DeMeester score >14.75 and/or >4% of pH<4 (at least 21 hours measured)

Exclusion Criteria:

  • Have food existence at stomach during upper GIS endoscopy, Barrett's stricture, GIS bleeding, malignite, and all type of GIS pathology to affects the study
  • Have allergy to the study drug or any of the excipients of the formulation
  • Must use of pain relieving medications (NSAIDs) during study, (paracetamol not excess of 2 gram/day can be used)
  • Use of any concomitant therapy which are drug affects the motility of GIS and acid secretion
  • Use of prostaglandin analogs and sucralfate
  • Have taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study
  • History of surgery of cholecystectomy
  • Abusing drugs or alcohol
  • Have a major psychiatric disease
  • Use of antidepressant (patient with minor depression or under controlled with drug can be included)
  • Have suppressed immune system or taken a immunosupressive treatment, including cortisone.
  • Have malabsorption, gastric outlet obstruction that affects the absorption of drug
  • Must use of drug ketoconazole, iron salts, digoxin, ampicilin esters , anticoagulants, antineoplastic agents
  • Women who are pregnant or of childbearing
  • Have gastroparesis
  • Current or a history of cancer, with the exception of fully excised skin carcinoma (Malign Melanoma will be excluded).
  • Have severe concomitant disease (i.e. uncontrolled or insuline dependent diabetes mellitus, symptomatic bladder stone (patients have asemptomatic, not undergone colesistit, stone <3cm and polib <1cm can be included), active or unhealed gastric or duodenum ulcer, Zollinger Ellison syndrome, primary esophageal motility disorder, pancreatitis, inflammatory bowel disease, chronic hepatic disease, severe lung disease, uncontrolled kidney failure, cardiac failure, cerebrovascular disease, epilepsy) which affects the conduct and result of study.

Sites / Locations

  • Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lansoprazole/Domperidone

Arm Description

DUOLANS 30/30 mg SR tablet per oral, one tablet daily

Outcomes

Primary Outcome Measures

The percentage time of 24-hour intragastric pH >4 compared to baseline
The AUC of 24-hour intragastric pH >4 compared to baseline

Secondary Outcome Measures

The significant increase in total measurements of median pH
The significant increase in nocturnal measurements of median pH
The decrease in reflux symptom index calculated by weekly regurgitation numbers
The decrease in reflux symptom index calculated by weekly pyrosis numbers
The percentage time of 24-hour intragastric pH >2 compared to baseline
The percentage time of 24-hour intragastric pH >6 compared to baseline
The AUC of 24-hour intragastric pH >2 compared to baseline
The AUC of 24-hour intragastric pH >6 compared to baseline
The percentage time of 24-hour total intragastric pH >4 compared to baseline
The AUC of 24-hour total intragastric pH >4 compared to baseline
The evaluation of gastric emptying by octanoic acid breath test compared to baseline
The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)

Full Information

First Posted
September 1, 2015
Last Updated
November 4, 2016
Sponsor
Neutec Ar-Ge San ve Tic A.Ş
search

1. Study Identification

Unique Protocol Identification Number
NCT02958046
Brief Title
The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity
Official Title
Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neutec Ar-Ge San ve Tic A.Ş

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).
Detailed Description
Objectives of the trial to assess the efficacy of lansoprazole in combination with domperidone on gastric acidity, intraesophageal acidity, GERD symptoms, impedance kinetics and gastric emptying in patients with GERD. 24 hour pH measurement and gastric emptying test will be done at screening visit and after 7 days of drug treatment. Twelve patients will take one tablet for 7 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lansoprazole/Domperidone
Arm Type
Experimental
Arm Description
DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Intervention Type
Drug
Intervention Name(s)
Lansoprazole/Domperidone
Other Intervention Name(s)
Duolans
Intervention Description
DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Primary Outcome Measure Information:
Title
The percentage time of 24-hour intragastric pH >4 compared to baseline
Time Frame
7 days
Title
The AUC of 24-hour intragastric pH >4 compared to baseline
Time Frame
7 days
Secondary Outcome Measure Information:
Title
The significant increase in total measurements of median pH
Time Frame
7 days
Title
The significant increase in nocturnal measurements of median pH
Time Frame
7 days
Title
The decrease in reflux symptom index calculated by weekly regurgitation numbers
Time Frame
7 days
Title
The decrease in reflux symptom index calculated by weekly pyrosis numbers
Time Frame
7 days
Title
The percentage time of 24-hour intragastric pH >2 compared to baseline
Time Frame
7 days
Title
The percentage time of 24-hour intragastric pH >6 compared to baseline
Time Frame
7 days
Title
The AUC of 24-hour intragastric pH >2 compared to baseline
Time Frame
7 days
Title
The AUC of 24-hour intragastric pH >6 compared to baseline
Time Frame
7 days
Title
The percentage time of 24-hour total intragastric pH >4 compared to baseline
Time Frame
7 days
Title
The AUC of 24-hour total intragastric pH >4 compared to baseline
Time Frame
7 days
Title
The evaluation of gastric emptying by octanoic acid breath test compared to baseline
Time Frame
7 days
Title
The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) during last one year with at least 1 or more episodes a week Age ≥ 18 years and <65 years Helicobacter pylori (an infection) negative Have a body mass index (BMI) between 18 and 33 kg/m² pH>4 gastric exposure <25% on a 24-hour dual pH channel monitoring study performed prior to screening (normal intragastric pH +2SD) Pathologic intraesophageal acidity exposure (DeMeester score >14.75 and/or >4% of pH<4 (at least 21 hours measured) Exclusion Criteria: Have food existence at stomach during upper GIS endoscopy, Barrett's stricture, GIS bleeding, malignite, and all type of GIS pathology to affects the study Have allergy to the study drug or any of the excipients of the formulation Must use of pain relieving medications (NSAIDs) during study, (paracetamol not excess of 2 gram/day can be used) Use of any concomitant therapy which are drug affects the motility of GIS and acid secretion Use of prostaglandin analogs and sucralfate Have taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study History of surgery of cholecystectomy Abusing drugs or alcohol Have a major psychiatric disease Use of antidepressant (patient with minor depression or under controlled with drug can be included) Have suppressed immune system or taken a immunosupressive treatment, including cortisone. Have malabsorption, gastric outlet obstruction that affects the absorption of drug Must use of drug ketoconazole, iron salts, digoxin, ampicilin esters , anticoagulants, antineoplastic agents Women who are pregnant or of childbearing Have gastroparesis Current or a history of cancer, with the exception of fully excised skin carcinoma (Malign Melanoma will be excluded). Have severe concomitant disease (i.e. uncontrolled or insuline dependent diabetes mellitus, symptomatic bladder stone (patients have asemptomatic, not undergone colesistit, stone <3cm and polib <1cm can be included), active or unhealed gastric or duodenum ulcer, Zollinger Ellison syndrome, primary esophageal motility disorder, pancreatitis, inflammatory bowel disease, chronic hepatic disease, severe lung disease, uncontrolled kidney failure, cardiac failure, cerebrovascular disease, epilepsy) which affects the conduct and result of study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neutec Ar-Ge San ve Tic A.S
Organizational Affiliation
Neutec Ar-Ge Clinical Trial
Official's Role
Study Director
Facility Information:
Facility Name
Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey
City
İzmir
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

We'll reach out to this number within 24 hrs